Posted by Michael Wonder on 04 Nov 2020
PASC to consider comprehensive genomic profiling of non-small cell lung cancer tumour tissue specimens using next generation sequencing assays
4 November 2020 - First consideration of next generation sequencing.
This application from Roche relates to the use of comprehensive genomic profiling of non-small cell lung cancer tissue using next generation sequencing assays in patients being considered for treatment with systemic therapy.
